医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
17期
197-198
,共2页
尿常规正常过敏性紫癜%病理特点%预后
尿常規正常過敏性紫癜%病理特點%預後
뇨상규정상과민성자전%병리특점%예후
Normal urine allergic purpura%Pathological features%Prognosis
目的:分析尿常规正常过敏性紫癜患儿临床病理特点及预后情况。方法:回顾性分析2013年7月~2014年7月在我院接受治疗的12例尿常规正常过敏性紫癜患儿,通过分析其临床资料,对其进行肾组织活检,做好常规检查,采用直接免疫荧光法对其肾组织呼吸道病毒进行检测。对所有患儿均进行为期6个月的随访。结果:经检测,所有患儿均存在不同程度的肾脏损害,病理分级多为I—IIIa,其中最常见的为IIb,肾组织中多种免疫复合物沉积最多;所有患儿24h尿蛋白均十分正常。结论:尿常规正常过敏性紫癜患儿在病情早期均有不同程度的肾脏损害,近期预后效果良好,需要长期随访掌握患儿病情变化。
目的:分析尿常規正常過敏性紫癜患兒臨床病理特點及預後情況。方法:迴顧性分析2013年7月~2014年7月在我院接受治療的12例尿常規正常過敏性紫癜患兒,通過分析其臨床資料,對其進行腎組織活檢,做好常規檢查,採用直接免疫熒光法對其腎組織呼吸道病毒進行檢測。對所有患兒均進行為期6箇月的隨訪。結果:經檢測,所有患兒均存在不同程度的腎髒損害,病理分級多為I—IIIa,其中最常見的為IIb,腎組織中多種免疫複閤物沉積最多;所有患兒24h尿蛋白均十分正常。結論:尿常規正常過敏性紫癜患兒在病情早期均有不同程度的腎髒損害,近期預後效果良好,需要長期隨訪掌握患兒病情變化。
목적:분석뇨상규정상과민성자전환인림상병리특점급예후정황。방법:회고성분석2013년7월~2014년7월재아원접수치료적12례뇨상규정상과민성자전환인,통과분석기림상자료,대기진행신조직활검,주호상규검사,채용직접면역형광법대기신조직호흡도병독진행검측。대소유환인균진행위기6개월적수방。결과:경검측,소유환인균존재불동정도적신장손해,병리분급다위I—IIIa,기중최상견적위IIb,신조직중다충면역복합물침적최다;소유환인24h뇨단백균십분정상。결론:뇨상규정상과민성자전환인재병정조기균유불동정도적신장손해,근기예후효과량호,수요장기수방장악환인병정변화。
Objective To analyze the normal urine in children with Henoch Schonlein purpura clinical pathological characteristics and prognosis. Methods A retrospective analysis of 2013 July~2014 year in July in our hospital for treatment of 12 cases of normal urine in children with Henoch Schonlein purpura, through the analysis of the clinical data, renal biopsy was performed on it, do the routine inspection, inspection of the renal tissue of respiratory virus by direct immunofluorescence method. All patients underwent 6 months of follow-up. Results All patients were detected, the existence of kidney damage in different degree, pathological grade is I~IIIa, one of the most common for IIb, a variety of immune complex deposition in renal tissue of all patients up;24h urine protein are normal. Conclusion Normal urine in children with Henoch Schonlein purpura early in the disease had different degree of kidney damage, the effect of the recent prognosis is good, need to grasp the long-term follow-up of children with the disease changes.